XBIO — Xenetic Biosciences, Inc.

Summary of XBIO Q1 2017 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended Q1 2017 with $4.3 million in cash, up from $4 million at the end of 2016, primarily due to a $3 million milestone payment from Shire, offset by operating losses.
• Equity: The company has approximately 2.2 million shares of Series B Preferred Stock outstanding, which can be converted to common stock at a 1:1 ratio.

2. Strategic Updates and Business Highlights

• Management Changes: Appointed Jim Parslow as CFO and Dr. Curt Lockshin as CSO.
• Partnerships: Received a $3 million milestone payment from Shire related to SHP656, a polysialylated Factor VIII product.
• Clinical Development: Filed a protocol for a biomarker study of XBIO-101 targeting triple negative breast cancer and is preparing to commence a Phase 2 study for progesterone-resistant endometrial cancer.
• Intellectual Property: Expanded patent portfolio in key markets, enhancing protection for its technologies.

3. Forward Guidance and Outlook

• Upcoming Milestones: Anticipate significant developments in Q2 2017, including the commencement of patient recruitment for the Phase 2 study of XBIO-101, announcement of top-line data from Shire for SHP656, and potential additional milestone payments from Shire.
• Long-term Strategy: Focus on advancing oncology therapeutics through to market launch, particularly in areas of unmet need and orphan diseases.

4. Bad News, Challenges, or Points of Concern

• Need for Capital: Acknowledged the necessity to secure additional capital to support ongoing operations and clinical trials.
• Dependency on Shire: The success of the SHP656 program is critical, and any delays or negative outcomes could impact future funding and partnerships.
• Market Competition: The hemophilia treatment market is competitive, and achieving differentiation through dosing frequency is essential for success.

5. Notable Q&A Insights

• Shire Update Expectations: Management expects a joint release with Shire regarding SHP656, detailing whether clinical endpoints were met, but specific clinical data will be retained by Shire.
• PolyXen Partnership Model: The Shire agreement is viewed as a template for future partnerships, particularly regarding milestone economics and market positioning.
• Patient Recruitment Projections: Anticipate activating around 20 clinical sites by the end of 2017 for the XBIO-101 trial, with interim data expected by the end of 2018 based on recruitment rates.

Overall, Xenetic Biosciences is positioning itself for potential growth through strategic partnerships and clinical advancements, while also facing challenges related to capital needs and market competition.